Neutrogena Skinclearing Mineral Powder Buff 30, Neutrogena Skinclearing Miner...

Description

Neutrogena SkinClearing® mineral powder in Chestnut 135 is a blemish treatment formulation that incorporates salicylic acid, known for its efficacy in treating and preventing breakouts. This product features MicroClear® technology, which enhances the delivery of active ingredients to the skin. The oil-absorbing powder is specifically designed to mattify the skin, providing a clear and smooth appearance. The net weight of the product is 0.38 ounces (11 grams).

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. The recommended application involves covering the entire affected area with a thin layer. This can be done one to three times daily, depending on the patient's needs and the physician's guidance.

It is advisable to initiate treatment with one application per day to minimize the risk of excessive drying of the skin. Based on the patient's response, the frequency may be gradually increased to two or three times daily as necessary or as directed by a healthcare provider.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the frequency of application to once a day or every other day to alleviate these symptoms.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of swallowing, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients that the application of this product may lead to skin irritation and dryness, particularly if used concurrently with other topical acne medications. In cases where irritation occurs, it is recommended that patients limit their use to one topical acne medication at a time to mitigate adverse effects.

It is imperative to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only. The use of this product in conjunction with other topical acne medications may increase the likelihood of skin irritation and dryness. In the event that irritation occurs, it is recommended that patients limit their use to one topical acne medication at a time to mitigate these effects.

Additionally, it is crucial to keep this product out of reach of children. If the product is swallowed, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of additional topical agents is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Neutrogena Skinclearing Mineral Powder Buff 30, Neutrogena Skinclearing Mineral Powder Chestnut 135, Neutrogena Skinclearing Mineral Powder Classic Ivory 10, Neutrogena Skinclearing Mineral Powder Honey 85, Neutrogena Skinclearing Mineral Powder Natural Beige 60, Neutrogena Skinclearing Mineral Powder Natural Ivory 20, Neutrogena Skinclearing Mineral Powder Nude 40, Neutrogena Skinclearing Mineral Powder Soft Beige 50 (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is advised.

For topical application, it is recommended to initiate treatment with one application daily to minimize the risk of excessive skin drying. Dosage may be gradually increased to two or three times daily as needed or directed by a healthcare professional. If patients experience bothersome dryness or peeling, the frequency of application should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Safety during pregnancy has not been established for salicylic acid. The use of salicylic acid is contraindicated in pregnant patients due to the potential risk to the fetus. Therefore, the use of salicylic acid during pregnancy should be avoided unless the potential benefits outweigh the risks. Healthcare professionals are advised to carefully consider the implications of treatment with salicylic acid in women of childbearing potential and to discuss alternative options when appropriate.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the potential risks and benefits.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event that the medication is swallowed, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Additionally, it is important to inform patients about the potential for skin irritation and dryness. They should be cautioned that using this medication concurrently with another topical acne treatment may increase the likelihood of these side effects. If patients experience irritation, they should be advised to limit their use to one topical acne medication at a time to minimize adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a manner that protects it from excessive heat, with a maximum temperature limit of 40°C (104°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The product is administered topically and is intended for external use only. Clinicians should advise patients that the use of multiple topical acne medications concurrently may increase the risk of skin irritation and dryness. If irritation occurs, patients are recommended to limit use to one topical acne medication at a time.

Additionally, it is crucial to keep the product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately.

Drug Information (PDF)

This file contains official product information for Neutrogena Skinclearing Mineral Powder Buff 30, Neutrogena Skinclearing Mineral Powder Chestnut 135, Neutrogena Skinclearing Mineral Powder Classic Ivory 10, Neutrogena Skinclearing Mineral Powder Honey 85, Neutrogena Skinclearing Mineral Powder Natural Beige 60, Neutrogena Skinclearing Mineral Powder Natural Ivory 20, Neutrogena Skinclearing Mineral Powder Nude 40, Neutrogena Skinclearing Mineral Powder Soft Beige 50, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)